v3.26.3
Collaboration and License Agreements - GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2026
Dec. 31, 2025
Collaboration and License Agreements      
Current portion of deferred revenue $ 10,501 $ 10,501 $ 9,387
Deferred revenue, net of current portion 2,180 2,180 8,113
GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”)      
Collaboration and License Agreements      
Deferred revenue     17,500
Fixed consideration amount     17,500
Research and collaboration revenue 1,900 4,900  
Current portion of deferred revenue 10,500 10,500  
Deferred revenue, net of current portion $ 2,200 $ 2,200  
GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) | Maximum      
Collaboration and License Agreements      
Variable consideration amount, commercial sales milestones     $ 440,000